Lyophitech develops a disruptive continuous lyophilization technology that introduces agitation during vacuum drying, contrasting with traditional static, batch plate lyophilizers. The company holds several families of proprietary patents and offers machine ranges for 7‑litre, 50‑litre and 1,000‑litre productions designed to meet GMP requirements. Its process aims to enable gentler, contact‑free confinement suitable for fragile products such as APIs, anaerobic probiotics, cytotoxic drugs, enzymes, peptides, oligonucleotides, stem cell master cells and monoclonal antibodies. Lyophitech was founded in 2017 and is based in Vénissieux, after many years of development. The firm plans to accelerate sales, with a priority on European markets, and to develop a fully automated machine tailored to the pharmaceutical industry. Management changes include the appointment of Marie‑Hélène Gramatikoff as CEO.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024